OBM Geriatrics

(ISSN 2638-1311)

OBM Geriatrics is an Open Access journal published quarterly online by LIDSEN Publishing Inc. The journal takes the premise that innovative approaches – including gene therapy, cell therapy, and epigenetic modulation – will result in clinical interventions that alter the fundamental pathology and the clinical course of age-related human diseases. We will give strong preference to papers that emphasize an alteration (or a potential alteration) in the fundamental disease course of Alzheimer’s disease, vascular aging diseases, osteoarthritis, osteoporosis, skin aging, immune senescence, and other age-related diseases.

Geriatric medicine is now entering a unique point in history, where the focus will no longer be on palliative, ameliorative, or social aspects of care for age-related disease, but will be capable of stopping, preventing, and reversing major disease constellations that have heretofore been entirely resistant to interventions based on “small molecular” pharmacological approaches. With the changing emphasis from genetic to epigenetic understandings of pathology (including telomere biology), with the use of gene delivery systems (including viral delivery systems), and with the use of cell-based therapies (including stem cell therapies), a fatalistic view of age-related disease is no longer a reasonable clinical default nor an appropriate clinical research paradigm.

Precedence will be given to papers describing fundamental interventions, including interventions that affect cell senescence, patterns of gene expression, telomere biology, stem cell biology, and other innovative, 21st century interventions, especially if the focus is on clinical applications, ongoing clinical trials, or animal trials preparatory to phase 1 human clinical trials.

Papers must be clear and concise, but detailed data is strongly encouraged. The journal publishes research articles, reviews, communications and technical notes. There is no restriction on the length of the papers and we encourage scientists to publish their results in as much detail as possible.

Archiving: full-text archived in CLOCKSS.

Rapid publication: manuscripts are undertaken in 8 days from acceptance to publication (median values for papers published in this journal in 2020, 1-2 days of FREE language polishing time is also included in this period). 

Current Issue: 2021  Archive: 2020 2019 2018 2017

Special Issue

Geriatric Cataract

Submission Deadline: October 30, 2021 (Open) Submit Now

Guest Editor

Michele Lanza, MD

Associate Professor, Multidisciplinary Department of Medical, Surgical and Dental Sciences, Università della Campania Luigi Vanvitelli, Napoli, Italy

Website | E-Mail

Research Interests:  Optometry and vision science; glaucoma; eyes; cataract surgery; clinical ophthalmology; eye diseases; optical coherence tomography; retinal diseases; vision science; OCT

About This Topic

Cataract, the opacification of the human eye lens, leads to a reduction of visual acuity and is largely, diffused among adults, affecting almost one hundred million people worldwide.

The only effective therapy for cataract is surgery and, currently, the standard treatment is phacoemulsification with intraocular lens (IOL) implant in the capsular bag.

Improvements in instrumentation, technology, training programs, surgical techniques, design of intraocular lenses, and medications have led cataract surgery to become a very safe and effective procedure, able to restore visual acuity and to improve quality of life. Consequently, the expectations of patients shifted from the need of restoring vision, with or without spectacles, to the demand of obtaining a very good visual acuity, without spectacles, and being disappointed in case of discomfort consequent to the surgical procedure.

Innovations and new tools are available are going to be in order to provide always better results in these patients.

A great effort is produced also in developing new IOL able to improve not just the far visual acuity but also to provide improvements in near vision and in the overall quality of vision.

The purpose of this special issue is to provide physicians information about last update in every topic of cataract disease from the diagnosis to the post-operative management.

Announcement
Newsletter

TOP